AcouSort AB (SE:ACOU)
:ACOU
Want to see SE:ACOU full AI Analyst Report?
Top Page
AcouSort AB
(ACOU)
Select Model
Select Model
Rating:51Neutral
Price Target:
kr4.50
▲(70.45% Upside)
Action:Reiterated
Date:05/29/26
The score is held back primarily by weak financial performance (persistent losses, negative gross profit, and negative/declining free cash flow) despite improving revenue and a debt-free balance sheet. Technicals are a relative positive with price above key moving averages and positive MACD, while valuation remains constrained by loss-making earnings and no stated dividend yield.
Positive Factors
Balance Sheet Strength
Zero reported debt materially reduces solvency and refinancing risk, giving the company flexibility to fund R&D, partnerships or commercialization without immediate borrowings. This conservative capital structure supports longer-term execution despite operating volatility.
Negative Factors
Unprofitable Operations
Negative gross profit and persistent operating losses indicate the core unit economics are currently unfavorable. Without structural improvements to product costs, yields, or pricing, revenue growth alone will not translate to profitability and long‑term self‑sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Zero reported debt materially reduces solvency and refinancing risk, giving the company flexibility to fund R&D, partnerships or commercialization without immediate borrowings. This conservative capital structure supports longer-term execution despite operating volatility.
Read all positive factors
AcouSort AB (ACOU) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr88.47M
Dividend YieldN/A
Average Volume (3M)29.24K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue Growth48.84%
EPS Growth49.66%
CountrySE
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding21,163,902
10 Day Avg. Volume27,764
30 Day Avg. Volume29,240
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.27
Price to Sales (P/S)7.79
P/FCF Ratio-3.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)kr10.70M
AcouSort AB Business Overview & Revenue Model
Company Description
AcouSort AB (publ) is a technology firm that innovates and provides automated systems for preparing biological samples. Their core methodology relies on acoustofluidics technology, catering to the needs of the research community and various life s...
How the Company Makes Money
null...
AcouSort AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.41M | 6.85M | 4.74M | 10.55M | 4.96M | 3.01M |
| Gross Profit | -7.92M | -14.50M | 4.77M | 8.39M | 2.91M | 548.00K |
| EBITDA | -10.95M | -14.33M | -15.89M | -16.70M | -12.86M | -11.46M |
| Net Income | -10.50M | -12.15M | -15.08M | -17.09M | -13.21M | -12.38M |
Balance Sheet | ||||||
| Total Assets | 26.52M | 17.89M | 12.32M | 34.51M | 42.66M | 36.56M |
| Cash, Cash Equivalents and Short-Term Investments | 14.57M | 6.29M | 3.57M | 23.99M | 33.97M | 31.52M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 12.79M | 1.59M | 3.86M | 10.38M | 22.54M | 3.54M |
| Stockholders Equity | 13.74M | 16.30M | 8.46M | 24.14M | 20.11M | 33.02M |
Cash Flow | ||||||
| Free Cash Flow | -8.30M | -17.27M | -19.84M | -31.77M | 2.95M | -12.23M |
| Operating Cash Flow | -7.78M | -16.78M | -18.81M | -31.56M | 3.96M | -10.92M |
| Investing Cash Flow | -460.00K | -488.00K | -1.02M | -1.16M | -1.01M | -1.31M |
| Financing Cash Flow | 19.06M | 18.98M | -157.00K | 22.08M | 0.00 | 35.63M |
AcouSort AB Technical Analysis
Neutral
2.64
Price Trends
4.05
Positive
3.36
Positive
3.13
Positive
Market Momentum
0.02
Positive
45.27
Neutral
49.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Neutral. The current price of 2.64 is below the 20-day moving average (MA) of 4.47, below the 50-day MA of 4.05, and below the 200-day MA of 3.13, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 45.27 is Neutral, neither overbought nor oversold. The STOCH value of 49.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACOU.
AcouSort AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | kr463.21M | 5.48 | -264.12% | ― | 147.35% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr88.47M | -8.42 | -79.59% | ― | 48.84% | 49.66% | |
51 Neutral | kr63.27M | -4.89 | -601.02% | ― | 45.42% | -24.68% | |
51 Neutral | kr106.06M | -4.33 | -202.18% | ― | -100.00% | -225.82% | |
43 Neutral | kr46.14M | -1.74 | ― | 8.47% | ― | ― | |
42 Neutral | kr34.40M | -0.40 | -88.65% | ― | -1.72% | 17.86% |
* Healthcare Sector Average
SE:ACOU
AcouSort AB
4.18
0.79
23.34%
SE:PILA
PILA PHARMA AB
1.39
-1.69
-54.92%
SE:ONCOZ
OncoZenge AB
7.55
2.21
41.39%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
1.47
-6.55
-81.67%
SE:LARK
CombiGene AB
2.33
-0.17
-6.80%
SE:SPRINT
Sprint Bioscience AB
4.39
3.88
757.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.